Video Latest - ecancer

Cytogenetic and proteomic prognostic markers of CLL

Dr Lauren Thurgood - Flinders University, Adelaide, South Australia

9 Sep 2015

Predicting progression and survival in CLL

Prof Jonathan Strefford - University of Southampton, Southampton, UK

9 Sep 2015

Phase I study of duvelisib in patients with relapsed or refractory CLL

Dr Susan O’Brien – University of California, Irvine, California, USA

$Phase I study of duvelisib in patients with relapsed or refractory CLL ( Dr Susan O’Brien – University of California, Irvine, California, USA )$

9 Sep 2015

The LRF CLL4 trial: long-term outcomes

Prof Daniel Catovsky - The Institute of Cancer Research, London, UK

9 Sep 2015

Expert panel discussion: The best of iwCLL 2015

Prof John Gribben, Prof Michael Hallek, Dr Michael Keating, Prof Kanti Rai

9 Sep 2015

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells

Dr Alexey Danilov - Oregon Health and Science University, Portland, USA

9 Sep 2015

Genetic deletions in CLL

Dr Carlo Croce - The Ohio State University College of Medicine, Columbus, USA

9 Sep 2015

Ethnic variations in CLL prevalence

Dr Thomas Chan - Queen Mary Hospital, Hong Kong, China

8 Sep 2015

Risk of bleeding-related adverse events in ibrutinib treated CLL patients

Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA

8 Sep 2015

Crystallography of the B-cell receptor immunoglobulin in CLL patients

Prof Paolo Ghia - San Raffaele University, Milan, Italy

8 Sep 2015

Epidemiology of CLL: Interlymph consortium and genome-wide sequencing studies

Prof Claire Vajdic - University of New South Wales, Sydney, Australia

8 Sep 2015

Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry

Dr Andrew Rawstron - St James Institute of Oncology, Leeds, UK

8 Sep 2015

Video